Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annovis Bio, Inc.

3.21
+0.16005.25%
Post-market: 3.300.0850+2.65%19:59 EDT
Volume:633.88K
Turnover:2.05M
Market Cap:62.55M
PE:-1.53
High:3.40
Open:3.09
Low:3.03
Close:3.05
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy,  MongoDB

Reuters
·
05 Jun

Annovis Bio Inc. Files Initial Statement of Beneficial Ownership for Andrew Walsh, Vice President of Finance

Reuters
·
17 May

Promising Alzheimer’s Treatment Advances: Analyst Recommends Buy for Annovis Bio

TIPRANKS
·
16 May

Annovis Bio Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
15 May

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, UnitedHealth, Wells Fargo

Reuters
·
15 May

Annovis Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results

Reuters
·
14 May

Annovis Bio Q1 EPS $(0.32) Beats $(0.36) Estimate

Benzinga
·
14 May

Annovis Bio Reports Widened Net Loss Per Share in Q1 2025 Despite Increased Cash Reserves

Reuters
·
14 May

Annovis Bio Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
07 May

BRIEF-Annovis Bio Appoints Hui Liu As Director Of Biostatistics

Reuters
·
29 Apr

Annovis Bio appoints Liu as Director of Biostatistics

TIPRANKS
·
29 Apr

Annovis Bio Appoints Hui Liu as Director of Biostatistics

THOMSON REUTERS
·
29 Apr

Press Release: Annovis Bio Appoints Hui Liu as Director of Biostatistics

Dow Jones
·
29 Apr

Annovis Bio Gets NYSE Noncompliance Notice

MT Newswires Live
·
28 Mar

Annovis Bio receives noncompliance notification from NYSE

TIPRANKS
·
28 Mar

Annovis Bio Faces NYSE Non-Compliance Notice

TIPRANKS
·
28 Mar

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the Nyse

THOMSON REUTERS
·
28 Mar

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

GlobeNewswire
·
28 Mar

Annovis Bio Inc : Maxim Group Cuts Target Price to $8 From $25

THOMSON REUTERS
·
25 Mar